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Abstract
Background: Three national HIV household surveys were conducted in South Africa, in 2002, 2005 and 2008. A novelty of
the 2008 survey was the addition of serological testing to ascertain antiretroviral treatment (ART) use.
Methods and Principal Findings: We used a validated mathematical method to estimate the rate of new HIV infections (HIV
incidence) in South Africa using nationally representative HIV prevalence data collected in 2002, 2005 and 2008. The
observed HIV prevalence levels in 2008 were adjusted for the effect of antiretroviral treatment on survival. The estimated
‘‘excess’’ HIV prevalence due to ART in 2008 was highest among women 25 years and older and among men 30 years and
older. In the period 2002–2005, the HIV incidence rate among men and women aged 15–49 years was estimated to be 2.0
new infections each year per 100 susceptible individuals (/100pyar) (uncertainty range: 1.2–3.0/100pyar). The highest
incidence rate was among 15–24 year-old women, at 5.5/100pyar (4.5–6.5). In the period 2005–2008, incidence among men
and women aged 15–49 was estimated to be 1.3/100 (0.6–2.5/100pyar), although the change from 2002–2005 was not
statistically significant. However, the incidence rate among young women aged 15–24 declined by 60% in the same period,
to 2.2/100pyar, and this change was statistically significant. There is evidence from the surveys of significant increases in
condom use and awareness of HIV status, especially among youth.
Conclusions: Our analysis demonstrates how serial measures of HIV prevalence obtained in population-based surveys can
be used to estimate national HIV incidence rates. We also show the need to determine the impact of ART on observed HIV
prevalence levels. The estimation of HIV incidence and ART exposure is crucial to disentangle the concurrent impact of
prevention and treatment programs on HIV prevalence.
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Introduction
Worldwide, South Africa has the highest number of HIV
infected individuals, with about 5.3 million people living with
HIV/AIDS, representing a quarter of the burden of HIV infection
in sub-Saharan Africa [1,2]. The National HIV&AIDS and STI
Strategic Plan 2007–2011 has begun to address this enormous
challenge for South Africa [3]. The two primary goals of the plan
are to reduce the HIV incidence rate by 50% and to expand the
access to antiretroviral treatment (ART) to 80% of people who
need it. South Africa’s scale-up of ART is unmatched in the world,
increasing from only 32,895 people on ART by January 2005 to
871,914 people enrolled in the public sector program by July 2009
(official statistics of the Department of Health, South Africa,
July 2009).
The interpretation of HIV prevalence trends in South Africa is
increasingly complex as the epidemic matured and prevention and
treatment programmes are implemented at the same time.
Increased access to ART has increased the survival time of people
living with HIV, with the effect that HIV prevalence is expected to
increase in the age groups who are predominantly receiving ART.
The estimation of HIV incidence is crucial in this evolving
scenario in order to disentangle the impact of prevention and
treatment programs on HIV prevalence.
Recently, a new method has been described that can estimate
HIV incidence by comparing prevalence data in two cross-
sectional prevalence surveys [4]. In this method, the difference in
prevalence between the two surveys is equal to effect of HIV/
AIDS-related deaths and new infections occurring during the
inter-survey interval; and with an estimate of AIDS deaths,
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validated using simulated data and through comparison of its
estimates with real measurements of incidence in several
community-based cohort studies in Africa [4]. The method has
since been used to estimate incidence in Tanzania and Zambia
where two cross-sectional prevalence surveys have been conducted
[5]. The validity of the estimate hinges on there being several
successive comparable surveys measuring national HIV preva-
lence in the general population.
Estimating incidence in this way is ideally suited to South
Africa, since there have been three large nationally representative
household-based surveys, in 2002, 2005 and 2008 [6]. Further-
more, the survey in 2008 identified individuals on ART by means
of testing HIV positive samples for the presence of antiretroviral
drugs, so that the effect of treatment on prevalence could be
accounted for adequately. These data can thus be used to derive
two estimates for the 2002–2005 and 2005–2008 inter-survey
intervals and identifying changes in incidence over time in recent
years.
Our objectives are (i) to attempt to quantify the impact of ART
on HIV prevalence following the rapid scale-up of access to
treatment, (ii) to calculate HIV incidence for two inter-survey
intervals and determine changes in incidence in recent years in
South Africa, and (iii) to examine changes in key behavioral
indicators collected in the three surveys among female youth aged
15–24 years.
Methods
Survey data
Three national HIV household surveys have been conducted in
South Africa, the first in 2002 followed by surveys in 2005 and
2008. Figure 1 shows the HIV prevalence profiles in the three
surveys by age and sex. All three surveys applied a multi-stage,
stratified sampling approach. The sampling frames for the surveys
were based on a master sample consisting of 1 000 enumerator
areas (EA) used by Statistics South Africa for the 2001 census. An
updated master sample had to be developed for the 2008 survey in
order to reflect the changing socio-demographic profile of the
country. The selection of EAs was stratified by province and
locality type. Locality types were identified as urban formal, urban
informal, rural formal (including commercial farms), and rural
informal. In the formal urban areas, race was also used as a third
stratification variable (based on the predominant race group in the
selected EA at the time of the 2001 census). The allocation of EAs
to different stratification categories was disproportionate with
over-sampling of EAs in areas that were dominated by Indian,
Coloured or White race groups to ensure that the minimum
required sample size in those smaller race groups was obtained [6].
The selected 1000 EAs formed the primary sampling units.
Visiting points, or households were used as secondary sampling
units. Within each household eligible individuals selected for the
survey represented the ultimate sampling unit. Weighting
procedures taking into account the complex sampling design and
HIV testing non-response produced a final sample representative
of the population in South Africa for the main reporting domains
sex, age, race, locality type and province. Individual sample
weights were benchmarked using the mid-year population
estimates provided by Statistics South Africa for the respective
survey years 2002, 2005 and 2008.
Structured questionnaires were used to collect demographic,
social and behavioural data. Oral mucosal transudate specimens
(n=8 428) were used in 2002, while in 2005 (n=15 851) and
2008 (n=15 031) dried blood spot (DBS) specimens were used for
HIV testing. The mid-points of data collection in the surveys were
June 2002, February 2005 and September 2008. HIV testing
coverage and non-response were analyzed for the main reporting
domains. Our detailed analysis comparing HIV risk-associated
characteristics in survey participants who were interviewed and
tested with those who were interviewed but refused HIV testing
suggests that the HIV survey results were not biased due to HIV
testing refusal [6].
Detection of antiretroviral drugs
In the 2008 survey, the presence of antiretroviral drugs (ARVs)
in HIV positive DBS samples was confirmed by means of High
Performance Liquid Chromatography (HPLC) coupled to Tan-
dem Mass Spectrometry. Qualitative detection of Lopinavir,
Ritonavir, Nevirapine, Efavirenz, Indinavir, Saquinavir, Zidovu-
dine, Lamivudine and Stavudine in DBS samples was carried out
by a validated method using minor modifications of the method
used by Koal et al. [7]. Antiretroviral drugs were extracted from
the DBS samples with 80% methanol and 20% 0.2M Zinc
Sulphate containing an internal standard. HPLC was carried out
on a Phenomonex Fusion RP column (56264mm) using a
methanol/10 mM ammonium acetate gradient to effect elution.
Detection of antiretroviral drugs was carried out using an Applied
Biosystems API 4000 tandem mass spectrometer in the multiple
reaction monitoring (MRM) detection mode for each drug using
appropriate MRM transitions. Blank and quality control cutoff
samples were included with each run. The limit of detection for
each drug was set at 50 ng/ml, a sensitivity set point which is
normally applied for quantitative monitoring of drug levels in the
blood. Values detected above this limit were considered as positive
and those below as negative.
Analytic Method
Our method for estimating incidence from two cross-sectional
prevalence measurements [4] is based on the synthetic cohort
principle, whereby we assume that individuals of age a in the first
survey will be represented by individuals aged azt in the second
survey, where t is the interval between surveys, even though the
surveys do not include the same individuals. The change in HIV
prevalence among individuals aged a in the first survey and azt
in the second survey can be attributed to incident infections and
AIDS deaths. By finding an approximate value for the rate of
AIDS deaths, based on the observed distribution of survival after
infection [8], HIV incidence for that age-group can be estimated.
Thus, using prevalence data collected in 2002 and 2005 an
estimate for incidence in the period 2002–2005 is found; and by
using prevalence data collected in 2005 and 2008, an estimate for
incidence in the period 2005–2008 is found. The interval between
the surveys (t) was 2 years 8 months for 2002–2005 and 3 years 7
months for 2005–2008, but since respondents reported only their
age in years at last birthday (rather than date of birth), it was
necessary to interpolate prevalence in the exact synthetic cohorts.
To allow for the effect of antiretroviral treatment in 2008, which
can prolong survival with HIV, the observed prevalence values
were changed to reflect HIV prevalence if no treatment were
available. This involves subtracting the proportion of HIV-infected
people who were alive in the survey that would have died without
treatment. This is closely related to the number of people receiving
treatment, but is actually lower because some of those on
treatment would have survived for some time even without
treatment. Thus, data on the scale-up of antiretroviral treatment
are used (Figure S1 in the Technical Appendix S1), and it is
assumed that treatment is typically initiated one year before
expected AIDS death [9]. This simple approach allows the
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mortality (for those not on ART) to be used correctly [5]. For
the point estimates, we assume that the mortality rate in the first
years on treatment is 10% per year. Further information on the
method is available in the technical appendix. This part of the
method had been validated with simulated data but not real cohort
data.
We use bootstrapping (repeating the incidence estimation with
prevalence values from simulated draws of a binomial model
representing the survey data) to determine how random errors in
the estimates of HIV prevalence in the survey propagate to errors
in the estimates of HIV incidence [10]. The uncertainty in the
estimates of incidence in 2005–2008 also includes the effect of
mortality during the first years on ART being lower (5% per year)
or higher (15% per year) than the rate assumed for the point
estimate. The results do not explicitly account for uncertainty in
the survival distribution following infection.
Results
In order to draw comparison between the prevalence estimates
obtained in 2002 and 2005, when a negligible number of
individuals were on treatment, with prevalence in 2008, when
17.5% of HIV-infected survey participants aged 15–49 years
tested positive for antiretroviral treatment, we make an adjustment
to the data in 2008. This adjustment removes those individuals
that are HIV-infected and currently receiving treatment and are
alive due to the effects of treatment. Assuming that the trend in the
numbers on treatment in the public sector reflects the overall
increase in treatment, and that treatment is typically initiated
approximately one year before individuals would otherwise die
[9,11,12] and that individuals starting treatment suffer a 10%
annual mortality rate in the first years of treatment [12,13], we
estimate that 58% of those receiving treatment in 2008 are alive
due to ART. The remaining 42% would therefore be expected to
be alive and present in the survey, even if they had not been
started on treatment.
Figure 2 shows the measured HIV prevalence level among men
and women in 2008, decomposed into those that are infected but
not on treatment (white areas), those on treatment that would
otherwise be alive (grey areas), and those alive due to treatment
(red areas). We thus calculate the increase (‘excess’) HIV
prevalence that is caused by antiretroviral treatment. Overall,
prevalence in 2008 among men and women aged 15–49 years was
16.9%. We estimate that the excess prevalence due to antiretro-
viral treatment in this age group is 1.7%, and that prevalence in
2008 in the absence of treatment would be 15.2%. Compared to
the estimate of prevalence in the same group in 2005 (16.2%), the
unadjusted value of prevalence in 2008 indicates a small increase,
whereas the adjusted value suggests a noteworthy decline.
Table 1 shows the excess prevalence by age and sex. The excess
HIV prevalence is highest among women 25 years and older and
among men 30 years and older. For example, among women aged
30–34 years, the observed HIV prevalence in 2008 is 29.1%, but
ART accounts for an excess prevalence of 3.6%, meaning that the
adjusted value of HIV prevalence without ART is 25.5%.
The overall estimates of incidence in the periods 2002–2005
and 2005–2008 are shown in Figure 3. The overall estimate of
HIV incidence in the period 2002–2005 for men and women aged
15–49 years is 2.0 per 100 person-years at risk (pyar) (95%
uncertainty range: 1.2–3.0). In 2002–2005, incidence was much
higher among women (2.8/100 pyar (2.1–3.9)) than men (1.0/
100 pyar (0.3–2.0)). Incidence was ten times higher among young
women aged 15–24 years (5.5/100 (4.3–6.6)) than men the same
age (0.5/100 (0.1–1.1)).
A lower HIV incidence rate of 1.3/100 pyar (0.6–2.1) was
estimated for women and men aged 15–49 years in the period
2005–2008. Overall, among adults aged 15–49, incidence declined
by35%betweenthetwointer-surveyperiods2002–2005 and 2005–
2008. This change did not reach statistical significance, however.
The decline overall was mostly due to changes in incidence among
young women aged 15–24, among whom there was a statically
significant 60% reduction in incidence to 2.2/100 pyar (1.3–3.1).
Incidence among men and women aged 25–49 years in 2005–2008
was similar to the estimates for the period 2002–2005.
In Figure 4 we focus our analysis of behavioural trends on the
female youth population since an incidence reduction was mainly
found among young women aged 15–24. While the percentage of
female youth reporting more than one sexual partner in the past
12 month did not essentially change from 2002 to 2008, very
significant changes were observed in condom use at last sex and
being tested for HIV. Self reported condom use increased from
46.1% in 2002 to 55.7% in 2005 and 73.1% in 2008. There was
also a substantial increase in the proportion of young women who
tested for HIV in the last 12 months, from 12.9% in 2005 to
29.8% in 2008. By 2008, more than half of 15–24 year-old women
(52.7% (49.6–55.9%)) had ever been tested for HIV, compared
with only one in eight (13.2% (10.8–16.2%)) just six years
previously in 2002. We also examined other variables such as
sexual debut, secondary abstinence, and intergenerational sex, and
found no substantive changes over the three surveys.
Discussion
In this analysis we have used a robust mathematical method for
estimating HIV incidence in South Africa using three measures of
HIV prevalence in large, nationally-representative household
surveys. The mathematical method has been shown to reliably
detect the level and age-pattern of HIV incidence and has
previously been validated by comparing the derived estimates to
‘gold-standard’ estimates of HIV incidence in cohort studies [5].
The availability of survey data collected in 2002, 2005 and 2008
allows, for the first time, a comparison of incidence estimates for
two inter-survey intervals. The data affords estimates of the
average HIV incidence rate – the number of new infections
occurring each year among 100 people susceptible individuals – in
the periods 2002–2005 and 2005–2008 and would be comparable
to the measure derived from a national HIV incidence cohort
study over these intervals. Such a national incidence cohort does
not exist for obvious reasons, including cost, feasibility, sampling
biases and ethical considerations. However, other independent
estimates of HIV incidence using a laboratory-based method for
recent infection and the ASSA model suggested similar levels of
incidence in 2005 [14,15].
Our estimate of incidence highlight that young women in South
Africa continue to face the highest risk of HIV infection of any
demographic group. However, our results also indicate that
incidence among young women has substantially reduced in recent
years. There is no strong indication of a reduction in incidence
among men or among older women. Nevertheless, the incidence
Figure 1. HIV prevalence in South Africa in (a) 2002, (b) 2005 and (c) 2008. The dark bars show the prevalence among men and the lighter
bars show the prevalence among women. Source: Human Science Research Council Surveys [6].
doi:10.1371/journal.pone.0011094.g001
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incidence among adults in South Africa overall by 35% between
2002–2005 and 2005–2008, although this was not statistically
significant. Despite this encouraging development, there is no
reason to become complacent. 1.3% of all uninfected South
African adults, including 2.2% of uninfected young women aged
15–24 years, became newly infected in the last year. These
incidence levels in the general population need to be halved in
order to meet the 2011 target of the National Strategic Plan [3].
An important factor in interpreting HIV prevalence data in the
era of ART is that prevalence can increase while HIV incidence is
unchanged, purely as a result of ART prolonging survival of HIV-
infected individuals. This means that records of prevalence
remaining constant could mask real declines in incidence [16].
For this reason, we adjusted the 2008 measurement of prevalence
to remove the effect of ART. This process introduces more
uncertainty in the estimates of incidence since the calculation
depends on the mean time of treatment initiation and rates of
mortality in the first years of treatment, for which there are no
direct empirical measurements in South Africa.
To address this, we made the adjustment and the estimation of
incidence under a range of assumptions to quantify the uncertainty
due to this approach (indicated in the error bars and uncertainty
intervals in Figure 3). Importantly, there remains clear evidence
for a reduction in incidence among women under all credible
assumptions for the effect of ART. Our analysis of the impact of
ART on the 2008 HIV prevalence levels showed that the effect
was predominantly among women in the age group 25–49 years
and among men 30 years and older. The increase of HIV
prevalence due to ART (‘excess prevalence’) was 3.6 percentage
points among women aged 30–34 years. The results argue strongly
for the inclusion of antiretroviral (ARV) testing in national HIV
survey protocols in order to enable a better informed interpreta-
tion of HIV prevalence data in the era of increasing ART
coverage. The added costs are relatively modest in the context of
the overall budget for a national cross-sectional survey.
Figure 2. The impact of antiretroviral therapy on HIV prevalence in 2008 for (a) men and (b) women. In each panel, the overall height of
the bars shows HIV prevalence; the white part shows those HIV-infected but not on treatment; the grey part shows those on treatment but who
would be still alive without treatment; and, the red part shows those on treatment who are alive due to treatment. The estimate of the proportion
alive due to treatment is based on assumptions that treatment is initiated one year before when individuals would otherwise die, and that individuals
on treatment suffer a 10% annual mortality rate in first years of treatment.
doi:10.1371/journal.pone.0011094.g002
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most robust and reliable way to measure HIV prevalence in the
general population [17]. Yet, biases in household surveys, in South
Africa and other African countries, can potentially be caused by
under-representing individuals not in households, e.g., mobile
individuals or those living in institutions (prisons, army barracks,
Table 1. Impact of antiretroviral therapy on HIV prevalence in South Africa 2008.
Age group (years)
HIV Prevalence
in 2005 (%)
HIV Prevalence
in 2008 (%)
Excess HIV Prevalence
due to ART in 2008 (%)
1
Adjusted HIV Prevalence
without ART in 2008 (%)
2
Men and Women
15–49 16.2 16.9 1.7 15.2
Men
15–19 3.2 2.5 0.8 1.7
20–24 6.0 5.1 0.0 5.1
25–29 12.1 15.7 0.9 14.8
30–34 23.3 25.8 2.5 23.3
35–39 23.3 18.5 2.6 15.9
40–44 17.5 19.2 2.0 17.2
45–49 10.3 8.4 1.9 6.5
50–54 14.2 10.4 1.0 9.4
15–49 11.7 11.6 1.3 10.3
Women
15–19 9.4 6.7 0.2 6.5
20–24 23.9 21.1 1.2 19.9
25–29 33.3 32.7 3.4 29.3
30–34 26.0 29.1 3.6 25.5
35–39 19.3 24.8 2.1 22.7
40–44 12.4 16.3 2.7 13.6
45–49 8.7 14.1 1.7 12.4
50–54 7.4 10.2 0.3 9.9
15–49 20.2 21.3 2.1 19.2
1The proportion of individuals who are alive because they are currently on ART and who would be dead otherwise.
2Estimated HIV prevalence if there was no ART in 2008.
doi:10.1371/journal.pone.0011094.t001
Figure 3. Estimates of HIV incidence rate in South Africa, 2002–2005 (light grey bars) and 2005–2008 (dark red bars), using cross-
sectional HIV prevalence data collected in 2002, 2005 and 2008. The error bars for the 2002–2005 estimates show the 95% uncertainty
interval due to measurement errors in the prevalence data; the error bars for the 2005–2008 estimates show the uncertainty due to measurement
error and the use of alternate assumptions for the ART adjustment (described in the text).
doi:10.1371/journal.pone.0011094.g003
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household populations had only a minimal effect on the national
estimates based on household survey populations [18,19]. Besides
successive cross-sectional surveys of the general population, the
other major source of information on trends in HIV prevalence
comes from prevalence estimates among women attending public
antenatal services. Contrary to the observation among young
women in the cross-sectional household surveys, the estimated
national HIV prevalence among South African pregnant women
remained stable over the past three years, 2006–2008 [1]. It would
be informative to test whether there was a trend in HIV
prevalence in the clinics that were included in all three years of
surveillance, removing the possibility that the selection of different
clinics has obscured a possible change.
However, extrapolations from antenatal data to the general
population should be made with caution. Pregnant women seeking
prenatal care at young ages are unlikely to be representative of
young females in the general population. Teenage pregnancy in
particular is an indicator for a socio-demographic and behavioural
risk profile that greatly increases the risk of HIV infection. In many
countries, including South Africa, antenatal estimates of preva-
lence at young ages are higher than estimates in the general
population [20,21]. Furthermore, prevalence trends observed in
public antenatal clinics may not mirror trends in prevalence in the
general population, if there are changes in age at first sex or
shifting patterns of fertility with respect to age [22]. Indeed, any
correlation between the degree of risk reduction among young
women and the likelihood of pregnancy, potentially mediated by
educational level or socio-economic background, could reduce an
observed change in antenatal prevalence. Studies in Zambia [23]
and Zimbabwe [24] have compared trends in prevalence
measured in the general population with estimates among women
attending local clinics and both found evidence that HIV
prevalence trends in antenatal clinics underestimated trends in
the general population, with the strength of this effect varying over
time and by socio-economic risk group. We therefore believe the
findings presented here are not necessarily contradictory to the
findings of the antenatal surveys, but rather result from inherent
differences associated with pregnant women served in public
health clinics.
The application of the method we used to estimate HIV
incidence for South Africa [4,5] is limited to the general
population at the national scale since there is a fundamental
assumption about individuals in different age-groups being
comparable [4]. For instance, 25 year-olds included in the 2005
survey and 28 year-olds included in the 2008 survey are drawn
from the same population. This would not be the case for
prevalence data obtained from sub-populations in which individ-
uals may enter and exit as they age (such as injecting drug-users or
sex workers). Therefore, an incidence analysis by specific risk
groups or socio-behavioural factors associated with increased risk
for HIV infection is beyond the scope of this method.
There are several potential factors that could have caused a
reduction in incidence. As epidemics mature, incidence can
decline as a natural course of the epidemic as those groups at most
risk of infection become saturated with infection and die [25].
However, this may be unlikely to have had a major role in driving
the incidence reduction among younger age-groups in an epidemic
as established as in South Africa. The scale-up of ART may have
the potential to reduce HIV incidence, since effective treatment
reduces viral loads and, as a consequence, the infectiousness of
infected individuals [26,27]. However, since access to treatment
has only increased significantly in recent years, it is expected that
such an effect would take longer to develop and require higher
levels of ART coverage for an extended period of time [16,28].
The national surveys in 2002, 2005 and 2008 do not suggest
substantial decreases in numbers of sexual partners, which have
been associated with changes in the epidemic in Uganda and
Zimbabwe [29,30]. However, there is evidence from the surveys of
a significant increase in condom use [6]. In 2002, 31% of men and
women aged 15–49 used a condom at last sex, but by 2008 this
had increased to 65%. The largest increases were among 15–24
year-old women (46% in 2002 to 73% in 2008) and 25–49 year-
old men (27% to 56%), and earlier modelling work has shown that
condom use in ‘cross-generational’ sexual partnerships (between
older men and younger women) could have a particularly large
effect on incidence among young women [31]. It not possible to
quantify the extent to which these changes in reported sexual
behaviour result from increasing social desirability bias [32],
although one can argued that reporting on the number of sexual
Figure 4. Key behavioural indicators among women aged 15–24 year in the 2002, 2005 and 2008 surveys. Indicators are: fraction
reporting two or more partnerships in the last 12 months, fraction reporting condom use at last sex, and fraction that reported having an HIV test in
the last 12 months. The question on testing in the last 12 months was not asked in 2002.
doi:10.1371/journal.pone.0011094.g004
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fully responsible for the observed changes. Further research is
therefore required to clarify the ways in which risk of infection has
been reduced, and the extent to which this can be attributed to
programmes.
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for the effect of antiretroviral therapy on survival.
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Figure S1 Scale-up of antiretroviral treatment. The thick grey
line shows the estimated numbers on ART in South Africa and the
dashed yellow line shows the fitted second-order polynomial, used
in the calculation for the trend in Tc. (Source: Department of
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